Fecal microbiota transplantation in human metabolic diseases: From a murky past to a bright future?

Nordin M.J. Hanssen, Willem M. de Vos, Max Nieuwdorp*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Fecal microbiota transplantation (FMT) is gaining considerable traction as a therapeutic approach to influence the course of a plethora of chronic conditions, ranging from metabolic syndrome and malignancies to auto-immune and neurological diseases, and helped to establish the contribution of the gut microbiome to these conditions. Although FMT procedures have yielded important mechanistic insights, their use in clinical practice may be limited due to practical objections in the setting of metabolic diseases. While its applicability is established to treat recurrent Clostridiodes difficile, FMT is emerging in ulcerative colitis and various other diseases. A particularly new insight is that FMTs may not only alter insulin sensitivity but may also alter the course of type 1 diabetes by attenuating underlying auto-immunity. In this review, we will outline the major principles and pitfalls of FMT and where optimization of study design and the procedure itself will further advance the field of cardiometabolic medicine.

Original languageEnglish
Pages (from-to)1098-1110
JournalCell Metabolism
Volume33
Issue number6
DOIs
Publication statusPublished - 1 Jun 2021

Keywords

  • diabetes
  • fecal microbiota transplant
  • metabolites
  • microbiome
  • responders

Fingerprint

Dive into the research topics of 'Fecal microbiota transplantation in human metabolic diseases: From a murky past to a bright future?'. Together they form a unique fingerprint.

Cite this